当前位置： SCI文献检索 > ALLERGY AND ASTHMA PROCEEDINGS期刊下所有文献 > Efficacy and tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis.

Efficacy and tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis.

Abstract：

:A new nasal aerosol solution formulation of ciclesonide containing a hydrofluoroalkane propellant (CIC-HFA) delivered via a metered-dose inhaler is currently in clinical development as a potential treatment for allergic rhinitis (AR). This study evaluated the efficacy and tolerability of CIC-HFA 74- or 148-microgram doses compared with placebo in patients with perennial AR (PAR). Patients ≥12 years of age with a ≥ 2-year history of PAR were randomized in a placebo-controlled, double-blind, parallel-group, multicenter study to CIC-HFA 74 micrograms, CIC-HFA 148 micrograms, or placebo q.d. in the morning (A.M.) for 26 weeks. Change from baseline in reflective total nasal symptom score (rTNSS), instantaneous total nasal symptom score (iTNSS), and rhinoconjunctivitis quality-of-life questionnaire with standardized activities (RQLQ[S]) in patients with baseline RQLQ of ≥3.00 were evaluated for the first 6 weeks of treatment. Treatment-emergent adverse events (TEAEs) were monitored throughout the study. Eleven hundred eleven patients were randomized. CIC-HFA 74- and 148-microgram doses showed statistically significant improvements in rTNSS (least squares [LS] mean change, 0.70 and 0.54, respectively; p ≤ 0.001 versus placebo for both), iTNSS (LS mean change, 0.58 and 0.42, respectively; p < 0.05 versus placebo for both), and RQLQ[S] (LS mean change, 0.55 and 0.37, respectively; p < 0.01 versus placebo for both) from baseline. The overall incidence of TEAEs was comparable between the CIC-HFA treatment groups and placebo. In this study, once-daily treatment with CIC-HFA 74- or 148-micrograms showed statistically significant improvements in nasal symptoms of PAR. Both doses were well tolerated. Clinical trial registration URL and registration number: www.clinicaltrials.gov/ct2/show/NCT00953147.

journal_name

Allergy Asthma Proc

journal_title

Allergy and asthma proceedings

authors

Mohar D,Berger WE,Laforce C,Raphael G,Desai SY,Huang H,Hinkle J

doi

10.2500/aap.2012.33.3522

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

19-26

issue

eissn

1088-5412

issn

1539-6304

journal_volume

pub_type

杂志文章,多中心研究,随机对照试验

在线工具

Efficacy and tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis.